Login to Your Account



As naloxegol nears end zone, Nektar seeks $108.4M for pipeline

By Marie Powers
Staff Writer

Friday, January 24, 2014
After pocketing a $70 million milestone payment from partner Astrazeneca plc in November following the FDA’s acceptance of the new drug application (NDA) for lead compound naloxegol, Nektar Therapeutics Inc. turned to the public markets in a big way to advance its internal programs.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription